

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	1837
Policy Title	Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid
Clinical Reference Group	Infectious Diseases
Which stakeholders were contacted to be involved in policy development?	Stakeholders registered under the Infectious Diseases CRG. A member of the British Thoracic Society MDR-TB Clinical Advice Service was part of the PWG and consulted the group during policy development. Expert clinicians were also consulted throughout the process.
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	British Thoracic Society – The Chair of the BTS MDR-TB Clinical Advice Service was on the PWG and this group have been consulted during the process and given feedback and support for the policy at stakeholder engagement.
Which stakeholders have actually been involved?	<p>The stakeholder engagement received 8 responses.</p> <ul style="list-style-type: none"> 2 from clinicians 2 from individuals 1 from British Thoracic Society 1 from British Infection Association 1 from UK Clinical Pharmacy Association 1 from North Central London TB Network – South Hub (Whittington/UCLH) <p>The key themes of the responses were:</p>

	<ol style="list-style-type: none"> 1. Clarity whether children are eligible for treatment with bedaquiline or delamanid for longer than 6 months and/or sequentially? This was updated and clarified within the policy proposition. 2. Question about monitoring being mandated for treatment, this is part of the licence of the drug and clinical consensus. 3. There were statements of support for the policy and inclusion of the updated 2018 WHO guidelines from 4 of the 8 responses received, from The British thoracic society, two clinicians and the north central network.
Explain reason if there is any difference from previous question	None.
Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	No further stakeholders.
How have stakeholders been involved? What engagement methods have been used?	The policy was circulated to stakeholders registered under the Infectious Diseases CRG and they were invited to comment.
What has happened or changed as a result of their input?	Clarification on patient eligibility criteria within the policy proposition document.
How are stakeholders being kept informed of progress with policy development	The PWG were given regular updates through the development of policy. The CRG received regular updates via the lead commissioner. The BTS MDR-TB CAS were consulted and updated via PWG membership.

as a result of their input?	
What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?	No further consultation is required as this is policy statement.